Q4FY26 Audited Financial Results

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+15.9%Reaction day

₹1857.00

prior close

₹2122.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.5%+17.4% vs market

Pharmaceuticals peers, median of 159sector-0.7%+16.6% vs sector

On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-1.5

15m

-0.4

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+15.9-1.5+17.4-0.7+16.6

Next day

+20.4-0.3+20.8+0.0+20.4

+19.3-0.3+19.6+0.2+19.1

+25.9+0.4+25.5+1.1+24.8

+25.2+0.3+24.9+0.3+24.9

+25.5+1.5+24.0+1.1+24.4

+24.4+2.3+22.1+1.7+22.7

15d

+23.2+1.5+21.7+1.1+22.1

+18.5+5.3+13.2+2.6+15.9

+32.4+7.8+24.6+8.0+24.4

+53.7+9.7+44.0+8.1+45.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma reported consolidated revenue from operations of ₹64,306.50 million for FY26, up 14.5% from ₹56,165.04 million in FY25. Profit after tax surged to ₹14,583.03 million from ₹7,539.13 million, representing a 93% year-on-year increase. EPS for FY26 stood at ₹62.35 per share (basic) compared to ₹42.40 in FY25. The statutory auditors (Deloitte Haskins & Sells) issued an unmodified opinion on the annual financial statements. The Board recommended a final dividend of ₹20 per equity share (2000% on face value of ₹1). An exceptional item of ₹243.46 million was recognized due to additional gratuity and leave liability provisions under the new Labour Codes effective November 2025.

Likely market impact

Strong PAT growth of 93% YoY significantly exceeds the 25% threshold, indicating robust profitability improvement. The clean audit opinion with no going concern issues reinforces financial health. The dividend of ₹20 per share provides direct shareholder returns.